AGL

agilon health Inc
NYSEHEALTHCAREMEDICAL CARE FACILITIES

Key Statistics

Market Cap
$1.79B
P/E Ratio
EPS
$-22.56
Beta
3.00
52W High
$125.71
52W Low
$7.48
50-Day MA
$83.01
200-Day MA
$34.88
Dividend Yield
Profit Margin
-6.09%
Forward P/E
178.57
PEG Ratio

About agilon health Inc

agilon health, inc. The company is headquartered in Long Beach, California.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$5.82B
Gross Profit (TTM)$-145.73M
EBITDA$-374.58M
Operating Margin0.71%
Return on Equity-109.60%
Return on Assets-14.20%
Revenue/Share (TTM)$351.06
Book Value$10.93
Price-to-Book10.21
Price-to-Sales (TTM)0.31
EV/Revenue0.284
EV/EBITDA-104.52
Quarterly Earnings Growth (YoY)301.00%
Quarterly Revenue Growth (YoY)-7.30%
Shares Outstanding$16.68M
Float$9.80M
% Insiders3.16%
% Institutions92.59%

Historical Volatility

HV 10-Day
HV 20-Day
HV 30-Day
HV 60-Day
HV Rank

Analyst Ratings

Consensus ($66.64 target)
4
Buy
11
Hold
2
Strong Sell

Latest News

agilon health Sets Date to Report Second Quarter 2026 Financial Results

WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the second quarter 2026 after market close on Wednesday, August 5, 2026 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 439-1904 for U.S. participants and +1 (585) 542-9983 for international participants and refe.

Business Wire7/7/2026Neutral
Why Fast-paced Mover Agilon (AGL) Is a Great Choice for Value Investors

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agilon (AGL) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Investment Research6/26/2026Positive
agilon health: Q1 Inflection And A New CEO Set Up A Multi-Year Rerating

agilon health is rated Buy with a $177 price target, reflecting a robust Q1 beat and a positive inflection in financials. Q1 2026 delivered $1.42B revenue (+$40M vs. consensus), $54M adjusted EBITDA (+162% YoY), and raised full-year guidance across all key metrics. Margin expansion is driven by a new data pipeline, scaled clinical programs, disciplined payer contracting, and AI-driven risk scoring now fully operational.

Seeking Alpha6/24/2026Positive

More HEALTHCARE Stocks

Data last updated: 7/9/2026